Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Wolfsteiner

P1.01-93 Quality of Life in Patients With Advanced NSCLC Treated in Second- Or Third-Line With Nab-Paclitaxel + Durvalumab: ABOUND.2L+

Journal of Thoracic Oncology

English

P1.01-70 Efficacy and Safety of Second- Or Third-Line Nab-Paclitaxel + Durvalumab in Patients With Advanced NSCLC (ABOUND.2L+)

Journal of Thoracic Oncology

English

Related publications

P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

Role of KRAS-LCS6 Polymorphism in Advanced NSCLC Patients Treated With Erlotinib or Docetaxel in Second Line Treatment (TAILOR)

Scientific Reports

Multidisciplinary

2015

English

Nab-Paclitaxel/Carboplatin Induction in Squamous NSCLC: Longitudinal Quality of Life While on Chemotherapy

Lung Cancer: Targets and Therapy

Oncology

2017

English

P1.01-48 Nab-Paclitaxel Plus Gemcitabine in Advanced NSCLC After Platinum-Based Chemotherapy: Final Results and Caveolin-1 Expression

Journal of Thoracic Oncology

English

216PD: Nab-Paclitaxel + Carboplatin (Nab-P/C) in Advanced Non-Small Cell Lung Cancer (NSCLC): Outcomes in Elderly Patients (Pts) With Squamous (SCC) Histology

Journal of Thoracic Oncology

English

P1.01-21 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control in ATLANTIC

Journal of Thoracic Oncology

English

Safety and Continuity of Second- And Third-Line Therapy With Paclitaxel or Irinotecan for Advanced and Recurrent Gastric Cancer

Molecular and Clinical Oncology

Cancer Research

Oncology

2014

English

P1.01-52 BR-34- Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Wolfsteiner

P1.01-93 Quality of Life in Patients With Advanced NSCLC Treated in Second- Or Third-Line With Nab-Paclitaxel + Durvalumab: ABOUND.2L+

P1.01-70 Efficacy and Safety of Second- Or Third-Line Nab-Paclitaxel + Durvalumab in Patients With Advanced NSCLC (ABOUND.2L+)

Related publications

P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Role of KRAS-LCS6 Polymorphism in Advanced NSCLC Patients Treated With Erlotinib or Docetaxel in Second Line Treatment (TAILOR)

Nab-Paclitaxel/Carboplatin Induction in Squamous NSCLC: Longitudinal Quality of Life While on Chemotherapy

P1.01-48 Nab-Paclitaxel Plus Gemcitabine in Advanced NSCLC After Platinum-Based Chemotherapy: Final Results and Caveolin-1 Expression

216PD: Nab-Paclitaxel + Carboplatin (Nab-P/C) in Advanced Non-Small Cell Lung Cancer (NSCLC): Outcomes in Elderly Patients (Pts) With Squamous (SCC) Histology

P1.01-21 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control in ATLANTIC

Safety and Continuity of Second- And Third-Line Therapy With Paclitaxel or Irinotecan for Advanced and Recurrent Gastric Cancer

P1.01-52 BR-34- Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC